Rectal Misoprostol as a Hemostatic Agent During Abdominal Myomectomy
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
Purpose is to identify if misoprostol in addition to local vasopressin decreases blood loss
when compared to vasopressin alone, which is our current practice at this time. The study
will be double-blinded with neither the patient nor the researcher knowing whether the
placebo or the misoprostol was given. We will monitor patients for decrease in hemoglobin and
hematocrit, need for transfusion, and operative time among other measures of perioperative
morbidity to see if the addition of misoprostol makes a significant difference. We will also
observe patients to see if there are any side effects of misoprostol that make its use
undesirable.
Phase:
Phase 4
Details
Lead Sponsor:
The University of Texas Health Science Center at San Antonio